Immunome (NASDAQ:IMNM) Shares Down 3.3%

Immunome, Inc. (NASDAQ:IMNM)’s stock price dropped 3.3% during trading on Friday . The stock traded as low as $16.44 and last traded at $16.61. Approximately 316,731 shares traded hands during trading, a decline of 54% from the average daily volume of 692,392 shares. The stock had previously closed at $17.18.

Analysts Set New Price Targets

IMNM has been the subject of several recent research reports. SVB Leerink initiated coverage on shares of Immunome in a research report on Monday, January 29th. They set an “outperform” rating and a $30.00 target price for the company. Guggenheim initiated coverage on shares of Immunome in a research report on Monday, April 15th. They set a “buy” rating and a $35.00 target price for the company. Wedbush boosted their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a research report on Monday, April 1st. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.67.

Immunome Trading Down 9.9 %

The stock’s 50-day simple moving average is $22.88 and its 200-day simple moving average is $14.91. The firm has a market capitalization of $924.00 million, a P/E ratio of -2.87 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). Immunome had a negative return on equity of 69.74% and a negative net margin of 761.92%. The firm had revenue of $3.83 million during the quarter, compared to the consensus estimate of $3.40 million. On average, equities research analysts expect that Immunome, Inc. will post -1.91 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. TD Asset Management Inc bought a new position in shares of Immunome during the 3rd quarter valued at approximately $1,063,000. Acadian Asset Management LLC bought a new position in shares of Immunome during the 3rd quarter valued at approximately $414,000. Emfo LLC bought a new position in shares of Immunome during the 4th quarter valued at approximately $633,000. Dorsey Wright & Associates bought a new position in shares of Immunome during the 3rd quarter valued at approximately $26,000. Finally, Renaissance Technologies LLC bought a new position in shares of Immunome during the 1st quarter valued at approximately $80,000. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.